Proteostasis Therapeutics (NASDAQ:PTI)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Friday, Zacks.com reports.
A number of other research analysts have also weighed in on PTI. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. Piper Jaffray Companies lowered their price objective on shares of Proteostasis Therapeutics to $5.00 and set an “overweight” rating on the stock in a research report on Thursday, May 9th. Finally, ValuEngine raised shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $8.75.
PTI opened at $0.69 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.30 and a quick ratio of 11.29. The firm’s 50-day moving average price is $0.90. Proteostasis Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $10.38. The company has a market capitalization of $36.00 million, a price-to-earnings ratio of -0.43 and a beta of -0.67.
A number of hedge funds have recently made changes to their positions in PTI. BlackRock Inc. raised its position in Proteostasis Therapeutics by 61.1% in the fourth quarter. BlackRock Inc. now owns 2,920,723 shares of the company’s stock worth $9,464,000 after acquiring an additional 1,107,731 shares during the period. Deutsche Bank AG raised its position in Proteostasis Therapeutics by 527.2% in the fourth quarter. Deutsche Bank AG now owns 321,121 shares of the company’s stock worth $1,040,000 after acquiring an additional 269,918 shares during the period. Acadian Asset Management LLC bought a new stake in Proteostasis Therapeutics in the first quarter worth about $290,000. Bank of New York Mellon Corp raised its position in Proteostasis Therapeutics by 331.6% in the fourth quarter. Bank of New York Mellon Corp now owns 268,990 shares of the company’s stock worth $871,000 after acquiring an additional 206,672 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Proteostasis Therapeutics in the second quarter worth about $178,000. 60.00% of the stock is currently owned by institutional investors and hedge funds.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
See Also: Support Level
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.